Nautilus Biotechnology, Inc. (NAUT) Stock Forecast
NAUT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $3.83 average of analyst targets
- Upside to target
- +86.1% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $-0.14
- 52-week range
- $0.85 – $3.95
NAUT analyst ratings
4 analystsNumber of analysts at each rating.
NAUT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NAUT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.15 | −$0.14 | −$0.11 | −29.5% | 4 |
| Current fiscal year (2026) | −$0.51 | −$0.53 | −$0.48 | −$0.47 | −9.0% | 4 |
| Next fiscal year (2027) | −$0.52 | −$0.63 | −$0.41 | −$0.51 | −1.9% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NAUT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $206,250 | $200,000 | $225,000 | 0.0% | 4 |
| Current fiscal year (2026) | $536,250 | $500,000 | $645,000 | 0.0% | 4 |
| Next fiscal year (2027) | $5.2M | $3.9M | $7.4M | +862.3% | 4 |
NAUT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NAUT revenue: reported and forecast
NAUT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.14 | −$0.14 | −$0.14 | −5.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.52 | −$0.51 | −$0.51 | −$0.51 | −$0.51 | −0.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.52 | −$0.52 | −$0.52 | −$0.52 | −$0.52 | +0.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NAUT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NAUT beat in 12 of 12.
What analysts expect from NAUT
4 analysts cover Nautilus Biotechnology; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.83, 86.1% above the latest close of $2.06. Analysts expect earnings of −$0.51 per share for 2026, −9.0% from a year earlier. For 2027 the average estimate is −$0.52 per share on revenue of $5.2 million. Nautilus Biotechnology beat the EPS estimate in 12 of the last 12 quarters.
Related: NAUT income statement, NAUT key metrics, NAUT chart. See the NAUT stock overview for the latest quote and news.
NAUT forecast FAQ
What is Nautilus Biotechnology's price target?
The average analyst price target for Nautilus Biotechnology is $3.83, 86.1% above the latest close of $2.06.
Is Nautilus Biotechnology a buy, hold or sell?
Of 4 analysts covering Nautilus Biotechnology, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nautilus Biotechnology's EPS forecast?
Analysts forecast −$0.51 per share for 2026 (range −$0.53 to −$0.48); for 2027 the estimate is −$0.52.
What is Nautilus Biotechnology's revenue forecast?
The average revenue estimate for 2026 is $0.5 million, growth of 0.0%; for 2027 it is $5.2 million.
When does Nautilus Biotechnology report earnings?
Nautilus Biotechnology is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 before the market opens; the EPS estimate is $-0.14.
Does Nautilus Biotechnology usually beat earnings estimates?
Nautilus Biotechnology reported EPS at or above the analyst estimate in 12 of the last 12 quarters.